Open AccessPrecision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
Author(s) -
Alessandro Laganà,
Itai Beno,
David Melnekoff,
Violetta V. Leshchenko,
Deepu Madduri,
Dennis Ramdas,
Larysa Sanchez,
Scot A. Niglio,
Deepak Perumal,
Brian Kidd,
Riccardo Miotto,
Jane Houldsworth,
Rita Shaknovich,
Ajai Chari,
Hearn Jay Cho,
Bart Barlogie,
Sundar Jagannath,
Joel T. Dudley,
Samir Parekh
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00019
Subject(s) - multiple myeloma , computational biology , precision medicine , medicine , biology , pathology
Multiple myeloma (MM) is a malignancy of plasma cells, with a median survival of 6 years. Despite recent therapeutic advancements, relapse remains mostly inevitable, and the disease is fatal in the majority of patients. A major challenge in the treatment of patients with relapsed MM is the timely identification of treatment options in a personalized manner. Current approaches in precision oncology aim at matching specific DNA mutations to drugs, but incorporation of genome-wide RNA profiles has not yet been clinically assessed.